- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04640246
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies.
The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity.
The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response to the tumor.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yosef Refaeli
- Phone Number: +1-720-859-3547
- Email: refaeli@taigabiotech.com
Study Contact Backup
- Name: Vivienne Margolis
- Phone Number: +972-52-4639634
- Email: vmargolis@taigabiotech.com
Study Locations
-
-
-
Petach Tikva, Israel
- Recruiting
- Rabin Medical Center
-
Principal Investigator:
- Salomon Stemmer, MD
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- Recruiting
- The Angeles Clinic and Research Institute
-
Principal Investigator:
- Inderjit Mehmi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for participation in the study:
- Histologically or cytologically confirmed diagnosis of malignant solid tumor/s
- Male or female subjects age 18 or older
- Metastatic tumor that has failed at least one line of therapy with further options being non-curative; or with metastatic tumor and patient declines standard of care therapies and alternatives offered, at the discretion of the investigator
- At least 28 days or 5 half-lives, since the last dose of medication to treat their malignancy.
- Measurable or evaluable disease by RECIST version 1.1
- Capable of understanding and complying with protocol requirements
- A life expectancy of greater than 12 weeks at Screening
- ECOG Performance Status of 0 to 2
- Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures
Adequate bone marrow, liver, and renal function at screening as defined below:
- hemoglobin ≥8.0 g/dL (transfusions allowed)
- total lymphocyte count ≥500/µL
- absolute neutrophil count ≥1500/µL
- platelet count ≥100,000/µL (transfusions allowed)
- alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of normal (ULN), or ≤5 times ULN for subjects with known hepatic metastases
- total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are present; subjects with a known history of Gilbert's syndrome (≤3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
- estimated glomerular filtration rate ≥50 mL/min/1.73 m2 (using Cockcroft Gault formula)
Exclusion Criteria:
Subjects who meet any of the following criteria will not be eligible for participation in the study:
- Pregnant or breast feeding
- Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted
- Active, symptomatic central nervous system (CNS) metastases. Subjects with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening and the Medical Monitor approves subject inclusion
- Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial
- Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident
- Women of child-bearing potential who are unable or unwilling to use an acceptable method of contraception
- Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (in USA: Known infection with human immunodeficiency virus [HIV], hepatitis B or hepatitis C that is not controlled and has any related symptoms)
- Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher
- Systemic lupus erythematous (SLE), inflammatory bowel disease, primary Sjogren's syndrome, rheumatoid arthritis, systemic sclerosis, and granulomatosis with polyangiitis; and any other autoimmune condition that, in the opinion of the investigator, may increase the risk of trial participation or trial drug administration, unless reviewed and approved by the medical monitor.
- Any hematopoietic malignancy
- Have more than one primary cancer diagnosis within the last 3 years
- Organ transplant or requiring immune suppression
- Bullous pemphigoid and other autoimmune diseases of the dermal-epidermal junction; these include bullous pemphigoid, bullous SLE, liner IgA disease, epidermolysis bullosa acquisita, and other pemphigoid variants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TBX-3400
TBX-3400 by intravenous infusion
|
Autologous transfusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary endpoint is the incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time Frame: 8 months
|
Adverse events from subject reporting
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Responses as defined by RECIST
Time Frame: 8 months
|
Tumor measurements to assess disease state
|
8 months
|
Assessment of concentrations of certain proteins such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Presence and/or concentration of anti TBX-3400 antibodies
Time Frame: 8 months
|
Measure of immunogenicity of TBX-3400
|
8 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification of the concentration of interleukin-1 (IL-1) in plasma
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Quantification of the concentration of interleukin-6 (IL-6) in plasma
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Quantification of the concentration of interferon-alpha (IFN-α) in plasma
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Quantification of the concentration of interferon-gamma inducible protein 10kD (IP-10) in plasma
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Quantification of the concentration of interferon-gamma (IFN-γ) in plasma
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Quantification of the concentration of transforming growth factor-beta (TGF-ß) in plasma
Time Frame: 8 months
|
Preliminary efficacy assessment to measure activity of TBX-3400
|
8 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TBX-3400-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on TBX-3400
-
Taiga Biotechnologies, Inc.RecruitingStage IV Melanoma | Stage III MelanomaUnited States
-
Taiga Biotechnologies, Inc.Not yet recruitingMyelofibrosis | Acute Myelogenous LeukemiaItaly, Croatia
-
Taiga Biotechnologies, Inc.Not yet recruitingSevere Combined ImmunodeficiencyIsrael
-
GeneOne Life Science, Inc.Inovio PharmaceuticalsCompletedHealthyKorea, Republic of
-
Jakob Stensballe, MD, PhDCellphire Therapeutics, Inc.Recruiting
-
A. Vogel AGTerminatedMenopausal Hot FlushesSwitzerland
-
Bispebjerg HospitalUnknownSunscreen Persistence | Vitamin D Production in the SkinDenmark